Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Secondary HRQoL domains in the KarMMa study of ide-cel in myeloma

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an analysis of secondary health-related quality of life domains (HRQoL) in the KarMMa study (NCT03361748): A Phase II trial of idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma patients. Ide-cel is a BCMA-targeted CAR T-cell therapy, shown to elicit deep responses in myeloma. Questionnaires were used at baseline, the day of treatment, and throughout follow up to assess the impact of ide-cel on secondary HRQoL domains. Overall, patients showed a clinically meaningful improvement in most functioning and symptom subscale scores with ide-cel treatment, as well as in future perspectives and body image. Symptoms such as nausea/vomiting, insomnia and diarrhea frequently remained stable. The results show that ide-cel can bring about clinical improvements without negatively impacting HRQoL domains. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research funding: Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar
Advisory role: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm